Drug combination for genetic lung disease
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests whether a combination of three medicines (azithromycin, hydroxychloroquine, and prednisone) can help people with scarring or inflammation in the lungs caused by certain genetic changes. It aims to see if these drugs can slow down or improve the lung disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 79 years old.
- You have a specific genetic change linked to lung disease (in genes like SFTPA1, SFTPA2, SFTPC, NKX2-1, SFTPB, or ABCA3).
- A CT scan within the last 2 years shows that more than 10% of your lung is affected by scarring or inflammation.
- You are not pregnant or breastfeeding, and if you could get pregnant, you agree to use reliable birth control for the study and for 22 months after.
- You are not in any other interventional research study.
- You can give informed consent and are affiliated with a health insurance system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This early-phase trial studies whether hydroxychloroquine can help children with certain genetic causes of interstitial lung disease (lung scarring/inflammation). It is designed for kids who are currently stable and have not recently taken hydroxychloroquine.
This Phase 2 study tests whether mycophenolate mofetil (MMF) can slow or improve early, mild lung scarring in people with systemic sclerosis. It’s meant for systemic sclerosis patients who have lung involvement on a CT scan but still have good breathing test results.
This trial tests efzofitimod to see if it can improve or slow lung disease caused by systemic sclerosis (scleroderma), and to check safety and side effects. It focuses on people with relatively early disease and measurable lung involvement on lung scans.
This trial is for people with scarring lung disease (pulmonary fibrosis) in Ireland. It aims to better understand and care for the condition, especially in families. The study will look at medical data and may help improve diagnosis and treatment.
This trial tests if a new drug called telitacicept works better than a standard lupus medicine (cyclophosphamide) to improve lupus-related lung scarring (interstitial lung disease). It might be an option if your breathing tests are still good enough.
Hear when a new Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.